Axsome Therapeutics, Inc.
AXSM
$118.51
$1.371.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.97M | -59.41M | -74.91M | -64.60M | -79.35M |
| Total Depreciation and Amortization | 2.25M | 2.13M | 2.07M | 2.06M | 1.99M |
| Total Amortization of Deferred Charges | 317.00K | 667.00K | 708.00K | 672.00K | 641.00K |
| Total Other Non-Cash Items | 27.32M | 23.39M | 33.13M | 38.21M | 23.72M |
| Change in Net Operating Assets | -14.33M | -10.15M | 12.80M | 5.03M | 22.88M |
| Cash from Operations | -32.42M | -43.38M | -26.20M | -18.63M | -30.11M |
| Capital Expenditure | -13.00K | -338.00K | -30.00K | -90.00K | -52.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -13.00K | -338.00K | -30.00K | -90.00K | -52.00K |
| Total Debt Issued | 190.00M | -- | -- | -- | -- |
| Total Debt Repaid | -192.51M | -401.00K | -330.00K | -311.00K | -186.00K |
| Issuance of Common Stock | 44.29M | 36.69M | 17.57M | 33.39M | 18.01M |
| Repurchase of Common Stock | -888.00K | -4.34M | -533.00K | -473.00K | -1.33M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.36M | -2.68M | -2.46M | -2.20M | -2.11M |
| Cash from Financing | 34.54M | 29.27M | 14.24M | 30.41M | 14.38M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.11M | -14.44M | -11.99M | 11.68M | -15.78M |